Healthcare / Medical DevicesWarsaw
$4.96
-0.17 (-3.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-7.9M · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$75M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-147.5%
↓Gross Margin
100.0%
↑Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-83.4%
FCF CAGR
—
FCF margin
-677500.0%
FCF / Net income
0.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1000.0 · net income $-11.2M · FCF $-6.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1000.00 | $1000.00 | $1000.00 | $40000.00 | $219000.00 |
| Net Income | $-11.2M | $-11.2M | $-9.0M | $-11.9M | $-7.1M |
| EBITDA | $-8.7M | $-8.7M | $-7.8M | $-11.2M | $-6.6M |
| EPS | -0.84 | -0.84 | -0.74 | -1.27 | -0.87 |
| Gross Margin | 100.0% | 100.0% | — | 22.5% | 58.4% |
| Operating Margin | -1106400.0% | -1106400.0% | -910600.0% | -28345.0% | -4641.1% |
| Net Margin | -1120800.0% | -1120800.0% | -901300.0% | -29820.0% | -3248.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.36 | 0.36 | 0.24 | 0.47 | 2.41 |
| Current Ratio | 2.82 | 2.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.8M | $-6.8M | $-11.5M | $-7.9M | $-5.7M |
| Returns | |||||
| ROE | -147.5% | -147.5% | -108.6% | -244.0% | -984.1% |
| Valuation | |||||
| P/B | 8.91 | 8.91 | 15.37 | 27.67 | 122.16 |
| Growth & Yield | |||||
| Revenue Growth | 0.0% | 0.0% | -97.5% | -81.7% | — |
| EPS Growth | -13.5% | -13.5% | 41.7% | -46.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.74 → -0.84
Residual
-30.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.